Maturity onset diabetes of the young in India - a distinctive mutation pattern identified through targeted next-generation sequencing

Summary Objective To establish and utilize a Next‐Generation Sequencing (NGS)‐based strategy to screen for maturity onset diabetes of the young (MODY) gene mutations in subjects with early‐onset diabetes. Patients and Methods Maturity onset diabetes of the young (MODY) genetic testing was carried ou...

Full description

Saved in:
Bibliographic Details
Published inClinical endocrinology (Oxford) Vol. 82; no. 4; pp. 533 - 542
Main Authors Chapla, Aaron, Mruthyunjaya, Mahesh Doddabelavangala, Asha, Hesarghatta Shyamasunder, Varghese, Denny, Varshney, Manika, Vasan, Senthil K., Venkatesan, Padmanaban, Nair, Veena, Mathai, Sarah, Paul, Thomas Vizhalil, Thomas, Nihal
Format Journal Article
LanguageEnglish
Published England Blackwell Publishing Ltd 01.04.2015
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Summary Objective To establish and utilize a Next‐Generation Sequencing (NGS)‐based strategy to screen for maturity onset diabetes of the young (MODY) gene mutations in subjects with early‐onset diabetes. Patients and Methods Maturity onset diabetes of the young (MODY) genetic testing was carried out in 80 subjects of Asian Indian origin with young onset diabetes to identify mutations in a comprehensive panel of ten MODY genes. A novel multiplex polymerase chain reaction (PCR)‐based target enrichment was established, followed by NGS on the Ion Torrent Personal Genome Machine (PGM). All the mutations and rare variants were confirmed by Sanger sequencing. Results We identified mutations in 11 (19%) of the 56 clinically diagnosed MODY subjects and seven of these mutations were novel. The identified mutations include p.H241Q, p.E59Q, c.‐162G>A 5′ UTR in NEUROD1, p.V169I cosegregating with c.493‐4G>A and c.493‐20C>T, p.E271K in HNF4A, p.A501S in HNF1A, p.E440X in GCK, p.V177M in PDX1, p.L92F in HNF1B and p.R31L in PAX4 genes. Interestingly, two patients with NEUROD1 mutation were also positive for the p.E224K mutation in PDX1 gene. These patients with coexisting NEUROD1–PDX1 mutations showed a marked reduction in glucose‐induced insulin secretion. All 24 subjects who had not met the clinical criteria of MODY were negative for the mutations. To the best of our knowledge, this is the first report of PDX1, HNF1B, NEUROD1 and PAX4 mutations from India. Conclusions Multiplex PCR coupled with NGS provides a rapid, cost‐effective and accurate method for comprehensive parallelized genetic testing of MODY. When compared to earlier reports, we have identified a higher frequency and a novel digenic mutation pattern involving NEUROD1 and PDX1 genes.
Bibliography:ark:/67375/WNG-7251BPC6-C
Council of Scientific & Industrial Research (CSIR), India
ArticleID:CEN12541
istex:E8C8BEE11335A8C4A5C6BEDD5920A7029DF68CC6
Table S1.Validation of 2GDMODY protocol by Sanger sequencing. Fig. S1. Ion Torrent PGM run report (314 chip). Fig. S2. A prototype Ion torrent suit coverage report [sample M60].
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0300-0664
1365-2265
1365-2265
DOI:10.1111/cen.12541